Skip to search formSkip to main contentSkip to account menu

Goserelin 10.8 MG Drug Implant [Zoladex]

Known as: GOSERELIN ACETATE 10.8 mg SUBCUTANEOUS IMPLANT [ZOLADEX], Zoladex 10.8 MG Drug Implant, Zoladex 10.8 MG Subcutaneous Drug Implant 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
This study aimed to prepare and optimize Goserelin Acetate (GOS) loaded hydrogel PLGA microsphere which is suitable for long… 
Highly Cited
2013
Highly Cited
2013
BACKGROUND Premature ovarian failure and infertility following chemotherapy in early breast cancer (EBC) are major concerns for… 
2013
2013
Eine wachsende Anzahl von Medikamenten mit unterschiedlichem Wirkmechanismus hat in den letzten drei Jahren zur Verbesserung des… 
2007
2007
BackgroundProstatic carcinoma is the second most common cause of cancer-related deaths in males in the West. Approximately 20% of… 
2006
2006
Der GnRH-Agonist Zoladex® (Z) (3,6 mg Goserelin; slow releasing depot-Praparat, s.c. alle 4 Wochen appliziert) hat sich als… 
2002
2002
  • W. Jonat
  • British Journal of Cancer
  • 2002
  • Corpus ID: 72094387
Correction to: British Journal of Cancer 2001; (Suppl 2): 1–5 An error has been noted within Figure 1. The chemotherapy regimen… 
Review
2001
Review
2001
  • W. Jonat
  • British Journal of Cancer
  • 2001
  • Corpus ID: 3068891
Current standard adjuvant therapies for premenopausal women with early breast cancer include ovarian ablation by surgery or… 
1990
1990
1990
1990
In einer offenen, randomisierten Multizenterstudie (Phase III) wurden die klinische Wirksamkeit und Vertraglichkeit der Goserelin…